A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop eye problems and be at risk for future vision loss.
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing | Psychedelic Invest
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel derivatives of
January 24, 2024